Prostate Cancer - Results from #820

REVIEW UroToday

Novel oncogene-induced metastatic prostate cancer cell lines define human prostate cancer progression signatures, "Beyond the Abstract," by Richard G. Pestell, MD, PhD, et al December 20, 2013

Hydrogel injection followed by treatment planning during radiotherapy of prostate cancer, "Beyond the Abstract," by Michael Pinkawa, MD December 20, 2013

Differential cytotoxic activity of a novel palladium-based compound on prostate cell lines, primary prostate epithelial cells and prostate stem cells, "Beyond the Abstract," by Fiona M. Frame, Engin Ulukaya, and Norman J. Maitland December 19, 2013

Metformin decreases glucose oxidation and increases the dependency of prostate cancer cells on reductive glutamine metabolism, "Beyond the Abstract," by Sarah-Maria Fendt, PhD December 16, 2013

Recommendations for prostate-specific antigen screening for prostate cancer: A national survey of radiation oncologists and urologists, "Beyond the Abstract," by Simon P. Kim, MD, MPH, et al December 12, 2013

A comprehensive review of the literature pertaining to serum testosterone levels after medical or surgical androgen deprivation, "Beyond the Abstract," by Tsutomu Nishiyama, MD, PhD December 11, 2013

Protein kinase A (PKA) pathway is functionally linked to androgen receptor (AR) in the progression of prostate cancer, "Beyond the Abstract," by Jenny L. Persson, PhD, et al December 11, 2013

Risk of mesothelioma following external beam radiotherapy for prostate cancer: A cohort analysis of SEER database, "Beyond the Abstract," by Francesco S. Violante, MD and Andrea Farioli, MD December 6, 2013

Endocytic adaptor protein epsin is elevated in prostate cancer and required for cancer progression, "Beyond the Abstract," by Kandice L. Tessneer, PhD, Satish Pasula, PhD, and Hong Chen, PhD December 4, 2013

Current and future urinary biomarkers for prostate cancer detection, "Beyond the Abstract," by Andreas Doll November 20, 2013

Promises and pitfalls of the novel anti-androgen Compound 30 in targeting enzalutamide resistance, "Beyond the Abstract," by Jennifer L. Bishop, PhD and Amina Zoubeidi, BSc, M.Sc, PhD November 15, 2013

The application of Prostate HistoScanning as a screening tool for prostate cancer, "Beyond the Abstract," by Vincent De Coninck, MD November 13, 2013

Prostate Health Index (Phi) and prostate cancer antigen 3 (PCA3) significantly improve prostate cancer detection at initial biopsy in a total PSA range of 2-10 ng/ml, "Beyond the Abstract," by Daniela Terracciano, et al November 12, 2013

Your selenium intake, your prostate, and “U,” "Beyond the Abstract," by David J. Waters, PhD, DVM November 11, 2013

Paradoxical metastatic progression following 3months of neo-adjuvant androgen suppression in the TROG 96.01 trial for men with locally advanced prostate cancer, "Beyond the Abstract," by James W. Denham, MD, FRANZCR November 8, 2013

Holmium:yttrium-aluminium-garnet laser for the treatment of urethral/bladder neck stricture after high-intensity focused ultrasound for prostate cancer, "Beyond the Abstract," by Won Jin Cho November 7, 2013

Investigation of (90)Y-avidin for prostate cancer brachytherapy: A dosimetric model for a phase I–II clinical study, "Beyond the Abstract," by Giovanni Paganelli, MD November 6, 2013

Cabazitaxel in patients with metastatic castration-resistant prostate cancer: Results of a compassionate use program in The Netherlands, "Beyond the Abstract," by Michel D. Wissing, et al November 4, 2013

Circulating MicroRNAs as biomarkers of prostate cancer, "Beyond the Abstract," by Luke Selth, PhD November 1, 2013

Outcomes of transperineal template-guided prostate biopsy in 409 patients, "Beyond the Abstract - Video," by James L. Symons October 31, 2013

Page 42 of 57